Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide in compensated MASH cirrhosis
NL-OMON61585Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis comparing Survodutide with Placebo (2 arms). Primary endpoint: Time to first occurrence of composite clinical endpoint. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on NL-OMON61585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61585.